Trial Profile

Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With Advanced and Hematological Malignancies Who Are Not Eligible for Fully Myeloblative Regimen.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fludarabine; Melphalan
Indications Acute myeloid leukaemia; Graft-versus-host disease; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

08 Jun 2015 Biomarkers information updated
04 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
04 Mar 2011 Planned end date changed from 1 Nov 2012 to 1 Oct 2010 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com